The p53 tumour suppressor gene

British Journal of Surgery

Volumn 85, Issue 11, 1998, Pages 1460-1467

  Steele, R J C ^a,b   Thompson, A M ^a   Hall, P A ^a   Lane, D P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER; CELL CYCLE; DNA DAMAGE; GENE EXPRESSION; GENE MUTATION; GENETIC STABILITY; HUMAN; MEDICAL LITERATURE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, P53; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031726889     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00910.x     Document Type: Article

References (87)

1. Bishop JM, Weinberg RA (eds). Scientific American Molecular Oncology. New York: Scientific American Incorporated, 1996.
2. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma virus is present in normal avian DNA. Nature 1976; 260: 170-3.
3. Spector DH, Varmus HE, Bishop JM. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc Natl Acad Sci USA 1978; 75: 4102-6.
4. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-6.
5. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-3.
6. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
7. Hall PA, Meek D, Lane DP. p53-integrating the complexity. J Pathol 1996, 180: 1-5 (Editorial).
8. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
9. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency development abnormalities in p53-deficient mice. Curr Biol 1995; 5: 931-6.
10. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet 1995; 10: 175-80.
11. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG. A teratologic suppressor role for p53 in benzo[a]pyrene-treated p53-deficient mice. Nature Genet 1995; 10: 181-7.
12. Norimura T, Nomoto S, Katsuki M, Gondo Y, Kondo S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nature Med 1996; 2: 577-80.
13. Hall PA, Lane DP. Tumor suppressors: a developing role for p53? Curr Biol 1997; 7: 144-7.
14. Hall PA, McKee PH, Menage HDP, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-7.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
16. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11: 3471-81.
17. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
18. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
19. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
20. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32.
21. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-6.
22. Lane DP, Hall PA. MDM2-arbiter of p53's destruction. Trends Biochem Sci 1997; 22: 372-4.
23. Mayo LD, Turchi JJ, Berberich SJ. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 1997; 57: 5013-16.
24. Shaulian E, Resnitzky D, Shifman O, Blandino G, Amsterdam A, Yayon A et al. Induction of Mdm2 and enchancement of cell survival by bFGF. Oncogene 1997; 15: 2717-25.
25. El-Deiry WS. P53, p21WAF1/CIP1 and the control of cell proliferation. In: Thomas T, ed. Cell Cycle Control and Apoptosis in Malignant Disease. London: Bios Scientific, 1995: 19-38.
26. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998; 273: 1-4.
27. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B et al. Further characterisation of the p53 responsive element-identification of new candidate genes for trans-activation by p53. Oncogene 1997; 14: 85-94.
28. Cox LS, Hupp T, Midgley CA, Lane DP. A direct effect on activated human p53 on nuclear DNA replication. EMBO J 1995; 14: 2099-105.
29. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-3.
30. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995; 9: 2170-83.
31. Schmale H, Bamberger C. A novel protein with strong homology to the tumour suppressor p53. Oncogene 1997; 15: 1363-7.
32. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389: 191-4.
33. Drane P, Barel M, Balbo M, Frade R. Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53. Oncogene 1997; 15: 3013-24.
34. Bian J, Sun Yi. p53CP, a putative p53 competing protein that specifically hinds to the consenus p53 DNA binding sites: a third member of the p53 family? Proc Natl Acad Sci USA 1997; 94: 14753-8.
35. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M et al. MDMX. a novel p53-binding protein with some functional properties of MDM2. Embo J 1996; 15: 5349-57.
36. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995; 108: 1843-8.
37. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996; 13: 2575-87.
38. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551-5.
39. Kern SE, Pietenpol JA, Thiagolingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-30.
40. Donehower LA, Harvey M, Stagle BL, McArthur MJ, Montgomery CA Jr, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21.
41. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
42. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-9.
43. Symonds H, Krall L, Reminton L, Saenz Robles M, Lowe S, Kacks T et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78: 703-11.
44. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman JT et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
45. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
46. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
47. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited. J Pathol 1994; 172: 1-4.
48. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179-89.
49. Thor AD, Moore DHH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
50. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965-70.
51. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992; 66: 758-64.
52. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106: 42-8.
53. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ et al. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994; 86: 681-7.
54. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859-62.
55. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 2018-23.
56. Bosari S, Viale G, Radaelli V, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993; 24: 1175-9.
57. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-4.
58. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. P53 in node-negative breast carcinoma: an immuohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821-30.
59. Poller DN, Baxter KJ, Shepherd NA. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997; 75: 87-93.
60. Baas IO, Mulder JW, Offerhaus B, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
61. Baas IO, van den Berg FM, Mulder JW, Clement MJ, Slebos RJC, Hamilton SR et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 1996; 178: 264-7.
62. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
63. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996; 16: 4961-71.
64. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.
65. Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov AV, Gudkov AV. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 1998; 391: 295-8.
66. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-68.
67. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742-6.
68. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N et al. The p53 gene is a potent determinant of chemosensitivity and radiosensisitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996; 122: 360-5.
69. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Vargaug JE et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-14.
70. Lutzker S, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 1996; 2: 804-10.
71. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn KW et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55: 1649-54.
72. Xu C, Meikrantz W, Schlegel R, Sager R. The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc Natl Acad Sci USA 1995; 92: 7829-33.
73. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 1992; 52: 6390-3.
74. Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54: 2914-18.
75. Potter MA, Morris RG, Ferguson A, Wyllie AH. Colorectal cancer mutations in whole gut lavage fluid. Br J Surg 1997; 84: 1590 (Abstract).
76. Mulcahy HE, Croke DT, Farthing MJG. Cancer and mutant DNA in blood plasma. Lancet 1996; 348: 628.
77. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51: 1744-8.
78. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-62.
79. Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996; 16: 3415-22.
80. Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T et al. Novel combination therapy for human colon cancer with adenvirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 1997; 73: 367-70.
81. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 9: 985-91.
82. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 1996; 274: 373-6.
83. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997; 3: 639-45.
84. Hupp TR, Lane DP. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp Biol 1994; 59: 195-206.
85. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270: 5405-11.
86. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83: 237-45.
87. Niewolik D, Vojtesek B, Kovarik J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 1995; 10: 881-90.